Leadership Insights into Pipeline Strategy: Balancing Science, Feasibility, and Commercial Value

David Jones
Jan 22
5 min read

Updated: Feb 18

Lessons from senior leaders across biotech and pharma on how portfolio decisions are made when effective clinical trial strategy is the goal.

How do leaders in pharma and biotech balance scientific innovation with operational and commercial realities in pipeline strategy?

In this panel session from COG Bay Area, senior executives share practical frameworks for portfolio decision-making, cross-functional alignment, and optimizing study progression—key for sponsors, CROs, and clinical operations teams.

This COG Bay Area session brought together a panel of experienced leaders representing biotech, pharma, and clinical development strategy: Raj Patel, Chief Operating Officer at Reac’s Pharmaceuticals; Nikhil Dube, Lifecycle Management Strategy Lead at Biogen; and Mukhtar Ahmed, Director of Project and Portfolio Strategy for Greenstone Biosciences. The conversation was moderated by Emily Roberts-Thomson, a development operations leader with deep expertise in startup environments.

Attendees heard firsthand how cross-functional leadership shapes which programs move forward, how resource allocation intersects with clinical trial feasibility, and what operational best practices underpin a resilient, ROI-driven portfolio.

Balancing Science, Feasibility, and Commercial Opportunity in Pipeline Decisions

One of the core challenges in clinical pipeline management is balancing robust science with business imperatives and real-world operational constraints. All panelists underscored that while scientific merit is critical, no organization can ignore the realities of return on investment (ROI), clinical trial risk, and the likelihood of getting a product to market.

Raj Patel highlighted the constant tension between scientific innovation and financial sustainability, especially in smaller companies. He noted, “As I moved up into the business part of the company, it became: What is the ROI? How soon am I going to get this product approved?” Survival, he explained, often depends on carefully weighing not just the promise of the science, but the path to regulatory approval and the capital required.

Nikhil Dube, representing a larger pharma viewpoint, framed pipeline decisions around three main pillars:

Scientific merit and risk appraisal
Development feasibility—including trial design and operational complexity
Commercial opportunity, specifically patient impact and revenue thresholds

Both Raj Patel and Mukhtar Ahmed reinforced the point that business discipline must define boundaries even when scientific conviction is high. For smaller biotechs, operational agility and a clear line-of-sight to human-relevant data are vital for attracting investors and advancing programs.

Cross-Functional Collaboration and Alignment

Pipeline strategy is never a technical calculation alone—it’s a cross-functional team sport. Both large and small organizations must navigate competing priorities, from research leads passionate about scientific novelty to commercial and executive teams focused on market access, timelines, and budget.

Emily Roberts-Thomson pointed out that “everyone sitting around the table, whether it’s research, whether it’s development, whether it’s commercial, it’s important that everyone is buying into the same decision.” Raj Patel recounted the reality of tough team debates, emphasizing how essential it is to reach consensus amid strong—and sometimes conflicting—leadership opinions.

In larger organizations, Nikhil Dube advised a two-stage process: first, cross-functional alignment to define baseline assumptions; second, focused scenario planning and risk mapping within each function (research, commercial, clinical ops, etc.) before reconvening for final governance review. This prevents endless circular debate and ensures input is actionable.

In smaller companies, where every team member wears multiple hats, Mukhtar Ahmed advocated total transparency and early, frequent dialogue—especially about translational feasibility and investor expectations. There’s little room for functional silos, and “scientific leaders, business leaders, and also people who are at the bench doing the studies” all need a clear line of sight to pipeline advancement criteria and clinical trial design feasibility.

Operational Feasibility: The Gatekeeper to Progression

Across company sizes, operational feasibility—especially trial design, patient recruitment, and startup timelines—has become an increasingly critical filter for pipeline prioritization. With clinical trials facing greater complexity and lengthier enrollment curves, programs perceived as operationally “doable” now have a real edge.

Leaders are increasingly mapping:

Precedent for clinical endpoints and their regulatory acceptance
The practicalities of country and site activation
Anticipated recruitment rates in light of competing studies and shrinking eligible patient populations

Nikhil Dube emphasized that “understanding what it would take to get a trial finished in time is definitely something that's now figuring into these pipeline decisions.” In an era of clinical trial outsourcing and complex vendor landscapes, strong governance and data-driven scenario planning are essential for both sponsors and CROs to deliver operationally viable studies.

The Influence of Investors and Boards

Especially in small and mid-size biotechs, investors and boards play an outsized role in set pipeline direction, governance, and funding allocation. Decisions often hinge on which projects are perceived as lowest risk for the highest near-term value, not simply on scientific promise.

Raj Patel gave a clear example of how shifts in the commercial landscape—like the growth of the drug abuse treatment market—can change board perception and willingness to fund a niche program. He shared, “It was very difficult to get the attention of the board that this is the technology or the product that they should go forward with… Finally the board saw the… the market changed, drug abuse became a big issue, and now let's put money behind it.”

Mukhtar Ahmed added that many investors now “want to see the clinical trial data before they want to even put in any money for development.” This arms-length approach raises the bar on early-phase study design, operational readiness, and the need to secure human-relevant data quickly to unlock future capital.

What This Means in Practice

For sponsors, CROs, and biotech leaders, the following practices can help align pipeline strategy with operational success:

Build cross-functional governance structures that encourage candid debate but drive toward actionable decisions
Use three-pillar frameworks (science, operational feasibility, commercial value) to create a balanced pipeline scoring model
Rigorously pressure-test feasibility early, including patient recruitment analysis and clinical trial outsourcing options
Keep investors and the board engaged with clear, realistic milestones and readiness to pivot if market dynamics change
Engage KOLs and external advisors early to validate the clinical trial design and reduce translational risk
Emphasize liquidity and timeline-to-data as much as novelty, especially in fundraising or capital-constrained environments

Key Takeaways

Portfolio decisions must weigh scientific merit, operational feasibility, and commercial potential in equal measure.
Robust cross-functional alignment is vital; functional silos and miscommunications can derail even the most promising programs.
Operational feasibility—particularly around study startup, recruitment, and outsourcing models—is now a central filter for go/no-go decisions.
Investors and boards increasingly demand early human data, so study design must prioritize speed-to-clinical proof.
Market shifts and external realities can (and will) reshape pipeline priorities—flexibility and scenario planning are essential.

Selected Quotes

“If you don’t have the funds, you might have the best science, but you’re not going to get anywhere.” — Raj Patel

“I would say three prongs in their totality inform the portfolio decision making: the science, development feasibility, and the overall commercial opportunity.” — Nikhil Dube

“The way I approach it is to first let science set the foundation, but business discipline has to then lay the boundaries and that is very important.” — Mukhtar Ahmed

“Silo has no place in a small biotech environment. There has to be transparency from the very beginning across all fronts…” — Mukhtar Ahmed

For more practical sessions, curated insights, and operational guidance, follow The COG Review: Building Better Clinical Studies or visit thepbcgroup.com.